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Abstract
With the improvement of -omics and next-generation sequencing (NGS) methodologies,
along with the lowered cost of generating these types of data, the analysis of high-through-
put biological data has become standard both for forming and testing biomedical hypothe-
ses. Our knowledge of how to normalize datasets to remove latent undesirable variances
has grown extensively, making for standardized data that are easily compared between
studies. Here we present the CAncer bioMarker Prediction Pipeline (CAMPP), an open-
source R-based wrapper (https://github.com/ELELAB/CAncer-bioMarker-Prediction-
Pipeline -CAMPP) intended to aid bioinformatic software-users with data analyses. CAMPP
is called from a terminal command line and is supported by a user-friendly manual. The pipe-
line may be run on a local computer and requires little or no knowledge of programming. To
avoid issues relating to R-package updates, a renv .lock file is provided to ensure R-pack-
age stability. Data-management includes missing value imputation, data normalization, and
distributional checks. CAMPP performs (I) k-means clustering, (II) differential expression/
abundance analysis, (III) elastic-net regression, (IV) correlation and co-expression network
analyses, (V) survival analysis, and (VI) protein-protein/miRNA-gene interaction networks.
The pipeline returns tabular files and graphical representations of the results. We hope that
CAMPP will assist in streamlining bioinformatic analysis of quantitative biological data,
whilst ensuring an appropriate bio-statistical framework.
Introduction
The availability of sensitive and specific biomarkers for disease diagnosis, prognosis, and mon-
itoring, is an attractive alternative to many of the current methods in use. The presence and
levels of certain tissue-derived molecular markers can help distinguish subtypes in heteroge-
neous diseases such as cancer [1,2]. Biomarkers may also be predictive of patient outcome and
responsiveness to treatment [3,4]. Alas, pinpointing robust cancer biomarkers may be a
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challenging endeavor. In a review from 2014, Yotsukura and Mamitsuka [5] showed that out
of 7720 publications on biomarkers usage, only 407 of these were patented, and none had
obtained FDA approval [5]. One of the main limitations of biomarker research often relates to
small sample size, yielding over-fitted and unreproducible results [6,7]. Other pitfalls include a
lack of standardized data curation [8], inappropriate statistical analysis, and lack of validation
[6,9,10]. Evaluation of marker specificity and sensitivity is pivotal as most cancer biomarkers
have high false-positive rates since a range of non-cancerous events may cause changes in lev-
els of specific biomolecules. Despite these limitations, macromolecular markers remain a
promising strategy for diagnosis and subtyping of cancer, as well as other diseases. With the
advancements in the field of high throughput data and the increased attention to data normali-
zation and statistical modeling, some drawbacks of biomarker mining may be overcome in the
foreseeable future [11].
Central to the identification of novel disease markers is the bioinformatic analysis of high
throughput biological data [12–16]. By applying different statistical tests and machine learning
approaches, researchers can go from large datasets with quantitative measurements to a few
biomolecules of interest [17–21]. Ideally, biomarker studies of the same disease should be rea-
sonably comparable; however, discrepancies of results are not at all uncommon. While some
of these differences arise from variances in study design and experimental procedures, a signif-
icant proportion is due to alternating and sometimes inappropriate data normalization and
bioinformatic analysis pipeline [22–24]. Standardizing the framework for the detection of bio-
marker candidates both in the wet lab [25], as well as the dry lab, should enable researchers to
more directly compare results across different studies and starting materials [24,26].
We here illustrate The CAncer bioMarker Prediction Pipeline (CAMPP), which is an R-
based command-line wrapper for the analysis of high throughput data. The intention behind
CAMPP is to provide bioinformatic software-users with a standardized way of screening for
potential disease markers, and other biomolecules of interest, prior to potential experimental
validation. We have aimed for a pipeline that is intuitive and well-documented, as is good
practice [27].
Design and implementation
Requirements
The main prerequisite for CAMPP is R and Rstudio. Furthermore, Macbook users must have
Xcode installed [https://developer.apple.com/xcode/], while windows users must ensure they
have some equivalent of command-line tools.
Currently, CAMPP is a command-line tool run using Rscript, which is automatically
acquired when installing R and Rstudio (most likely path; /usr/local/bin/Rscript). Minimum
requirements; R version 3.5.1 and Rstudio version 1.1.463.
Set-up and package stability
The first time the pipeline is run, all R-packages and dependencies are automatically checked
and installed. For installation, a default CRAN mirror is employed; however, this may easily be
changed to better fit user location (https://cran.r-project.org/mirrors.html).
Renv: As updates of R-packages are regular, there is a chance that the code will break, and
we therefore also provide the user with the option to use an R-package “freeze”, in the form of
a renv [28]. To use the renv packages, the user must run CAMPP with the argument flag, -e, set
to “stable”.
The CAMPPFunctions.R contains custom functions sourced by the CAMPP.R script (main
script), and, as such, these two scripts must be located in the same working directory.
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CAMPP may be used to perform a variety of analyses, including preliminary data manage-
ment, summarized in Table 1 and Fig 1A below. As the analyses with CAMPP are standard-
ized, the pipeline accepts a range of biological datasets from different high throughput
sequencing platforms.
User input
The user must provide; (I) a matrix with expression/abundance values, (II) a metadata file
which should contain at least two columns, a column with sample ids, matching the column
names in the expression/abundance file and a column specifying which group (disease state,
treatment etc.) a given sample belongs to and (III) the user has to specify which type (variant)
of data is provided for analysis, current options are; array, seq, ms or other.
Value imputation and pseudocounts
If the input data contains missing expression values, these will automatically be imputed using
Local Least Squares Imputation, LLSI [29], or K-Nearest Neighbor Imputation, KNNI [30].
The default method is LLSI, as this type of imputation has been shown to perform better on
expression data [31].
Data normalization, filtering, and transformation
For RNA sequencing data (seq) variables with low counts over all groups (tissue, treatment)
are filtered out, library sizes are scaled (weighted trimmed mean of M-values, TMM) [32], and
data are voom-transformed [17]. For microarray data, (array) data are log2-transformed and
either quantile normalized [32,33] or standardized using mean or median [34]. Mass spec-
trometry data (ms), are log-transformed (log2, log10, or logit) and standardized using mean or
median [34].
Table 1. Table summarizing preliminary data management and analyses implemented in CAMPP, along with
specific methods and underlying R-packages.
Type R-package
Preliminary Data Management
Missing Value Imputation K-nearest neighbor impute [30]
Data Normalization Normalize between arrays and mean/median
centering
R Base
Data Transformation log2, log10, logit, voom R Base
Data Distribution Fitting Normal, Weibull, Lognormal, Gamma,
Poisson, Binomial
fitdistrplus [35]
Analysis
K-means Clustering Hartigan and Wong algorithm, BIC R Base, mclust [36]
Differential Expression/Abundance
Analysis
Empirical Bayes Framework for Linear Models edgeR [32], limma [37],
sva [41]
LASSO / Elastic-Net Regression Group LASSO/EN—multinomial glmnet [42], pROC [43]
Co-Expression/Abundance
Correlations
WGCNA, Pearson, Spearman WGCNA [44], R Base
Survival Analysis Cox Proportional Hazard Regression survcomp [45]
Interaction Networks STRING [47], miRTarBase [48] and
TargetScan [49]
multiMiR [50]
https://doi.org/10.1371/journal.pcbi.1007665.t001
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Fig 1. A. Diagram depicting the different types of methodologies and analyses employed by the CAncer bioMarker Prediction Pipeline
(CAMPP). B. Diagram depicting the structure of CAMPP output, with folders and subfolders organized by analyses.
https://doi.org/10.1371/journal.pcbi.1007665.g001
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Preliminary data distributional checks
As default, the pipeline utilized the R-package fitdistrplus [35] to generate skewness-kurtosis
plots (Cullen and Frey graphs) for ten randomly selected variables. Distributions are fitted to
data by maximum likelihood, and parameters of the distribution are estimated with bootstrap-
resampling to simulate variability [35]. In addition to the Cullen and Frey graphs, histograms,
quantile-quantile, and probability-probability plots are returned.
Clustering of samples
CAMPP will test several of centroids for K-means clustering, the exact number of which will
depend on the size of the dataset. After clustering, the R-package mclust [36] is employed to
evaluate which number of clusters is “optimal” for the input data, based on the Bayesian Infor-
mation Criterion (BIC). The pipeline will return an Multidimensional Scaling (MDS) plot
depicting the “best” clustering of samples. In addition, CAMPP will output the original meta-
data file with a column specifying which cluster each sample was assigned to. If desired, the
user may re-run CAMPP, using the k-means column for variable selection.
Variable selection with differential expression analysis and elastic-net
regression
Variable selection with CAMPP employs limma (linear models for microarray data) for differ-
ential expression/abundance analysis (DEA, DAA) [37]. Limma was originally designed for
analysis of microarray data and subsequently revised to handle RNA sequencing data. How-
ever, this software is very flexible and has recently been shown to also perform very well with
quantitative mass spectrometry data [38,39]. In addition to being versatile, limma has been
shown to work exceptionally well on datasets with small sample sizes [17,40]. DEA may be per-
formed with correlation for experimental batches and other confounders. Batch-correction is
performed by directly incorporating batches into the model design matrix [41]. Batch correc-
tion is achieved by specifying the name of the column in the metadata file, which contains the
batch information (with flag -b)—see user manual for specifics.
As DEA most often yields a long list of variables, CAMPP also performs Least Absolute
Shrinkage and Selection Operator (LASSO) or Elastic Net (EN) regression with glmnet [42].
EN/LASSO may be performed in two ways; (I) the dataset is split into training and testing
subsets, k-fold cross-validation is performed on the training dataset, followed by estimation of
specificity and sensitivity (area under the curve = AUC) [43] using the test dataset, or (Il) k-
fold cross validation is performed using the full dataset. CAMPP will automatically estimate
whether the input dataset is large enough to split. The pipeline will perform regression analysis
ten times and output bar-plots of cross-validation errors and AUCs for each run. Results of
DEA, LASSO/EN regression, and the overlap between these are output in tables.
Weighted co-expression network analysis
CAMPP may be used to perform Spearman correlation analysis, with testing for significance
and correction for multiple testing (FDR). The user may perform a Weighted Gene Co-
Expression Network Analysis. For this type of analysis, CAMPP relies on the R-package
WGCNA [44]. To reduce the contribution from low correlations, mainly assumed to be noise,
the WGCNA software estimates soft thresholding powers for exponentiation. Co-expression
analysis will result in a plot of variable clustering, before merging and after merging of mod-
ules (modules with < 25% dissimilarity are merged by default). A heatmap showing the
strength of variable co-expression within each module will be generated, if the module
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PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007665 March 16, 2020 5 / 20
contains < = 100 variables—more than this will yield an unreadable plot. CAMPP will return
tabular .txt files, one from each module, with the topmost interconnected variables within a
module (default is 25%) and accompanying interconnectivity score plots.
Survival analysis—Pinpointing prognostic biomarkers
Users may perform survival analysis with Cox proportional hazard regression [45] within
CAMPP. To run survival analysis, the provided metadata file must contain at least three col-
umns; age = age in years at diagnosis, surgery, or entry into trial, outcome.time = time until the
end of follow-up and outcome = specifying censuring or death (0 or 1). In addition to age, the
user wishes to correct for other potential confounders. The pipeline checks two underlying
assumptions of the Cox model before performing survival analysis: (I) a linear relationship of
continuous covariates with log hazards, and (II) proportional hazards of categorical and con-
tinuous covariates, i.e., constant relative hazard [46]. If the requirement of linearity is not ful-
filled, cubic splines will be added to the covariate(s) in question.
Interaction networks
After variable selection, the user may generate protein-protein and/or miRNA-gene interac-
tion networks. If gene expression data are used as input for CAMPP, protein-protein interac-
tions are retrieved from the STRING database [47], and pairs, where both genes (proteins) are
differentially expressed, are extracted. The pipeline can accept a variety of gene identifiers. If
miRNA expression data are used as input, then miRNA-gene interaction pairs are retrieved
from either miRTarBase (validated targets) [48], TargetScan (predicted) [49], or a combination
of both [50]. Mature miRNA identifiers or miRNA accession are allowed as input. If the user
has both gene and miRNA expression values from the same sample cohort, both protein-pro-
tein and miRNA-gene pairs are retrieved, and the results are combined. In this case, the pipe-
line will return pairs where the fold changes of gene and miRNA are inverse, one up-regulated
and the other down-regulated. Interaction network analysis with CAMPP will result in a tabu-
lar .txt file with all extracted interactions, including logFCs, FDRs, and interaction scores. This
file may be used for visualization of networks with Cytoscape [51] or another similar tool. In
addition, a plot of the top 100 “strongest” interactions are returned.
Results
Case Study 1
Analysis of Single-Channel Microarray Data, Variable Selection, WGCNA and, Gene-Gene
Interactions.
For the testing of an array dataset, we used mRNA expression data from single-channel
microarrays [52]. The dataset contained 80 breast tumor samples with expression quantified
for ~ 15.000 mRNAs. Clinical data included, among other things, information on the classifi-
cation in breast cancer subtypes. Data were background-corrected for ambient intensities
before analysis.
We used CAMPP to perform variable selection. Missing values were imputed, data were
log2 transformed and normalized between arrays. Additionally, data were corrected for experi-
mental batches and tumor immune scores. Variables with the ability to separate patient estro-
gen receptor status (ER+ vs. ER-) were selected with elastic-net (alpha = 0.5) and DEA. For
this contrast, patient distribution across the two groups was balanced, and CAMPP divided
the data into training and testing sets. Subtype-specific expression profiles were also compared;
however, as only nine samples where available for one of the subtypes, elastic-net regression
PLOS COMPUTATIONAL BIOLOGY CAMPP - A standardized framework for the analysis of biological data
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was performed without splitting the dataset. As the lack of a test set increases the chance of
overfitting significantly, elastic-net results merely provided support for DEA results.
Fig 2 shows an example of the data checks performed with fitdistrplus [35] on a set of n
(default is 10) randomly extracted variables from the dataset. The gene used as an example in
Fig 2 is FAM27E2 (Family With Sequence Similarity 27 Member E2), randomly selected from
the ten data check plots. FAM27E2 and the other nine genes tested by random, all displayed
approximate normal distributions, indicating that these were appropriate for further analysis
(see specifics on this in user manual in the GitHub repository). Fig 3 shows the number of up-
and down-regulated genes from DEA overlapped with results of elastic-net regression, for the
comparison of estrogen receptor status (ER- vs. ER+). Fig 3 also contains a MDS plot for data-
overview and statistics on cross-validation error and area under the curve (AUCs) for each of
the ten elastic-net runs. Lists of DE genes, results of LASSO regression, and all plots may be
found in the GitHub repository (CS1.zip).
As seen from Fig 3B, a total of 147 genes were found to be down-regulated in ER- vs ER+
(up in ER+), while 156 genes were up-regulated in ER- vs. ER+ (down in ER+). Elastic-Net
regression resulted in 20 genes, out of which nine overlapped with DEA results. Plots of cross-
validation errors and AUCs displayed good convergence, with AUCs ranging between 0.96–
1.0. The inspection of the nine genes from the overlap between DEA and elastic-net revealed
that two of these were Estrogen Receptor 1 and RAS Like Estrogen Regulated Growth Inhibi-
tor, both up-regulated in the ER+ samples compared to ER- samples, in accordance with
expectation [53]. Two of the genes which were up-regulated in ER-negative samples encoded
for solute carriers, known to be associated with more aggressive types of breast cancer [54–56].
The heatmap in Fig 4 shows the partitioning of breast tissue samples based on the consensus
set of variables from DE analysis and elastic-net regression.
In summary, a total of 290 genes were differentially expressed between subtypes, out of
which 20 were also identified by elastic-net regression—in total elastic-net returned 42 genes.
The set of 20 consensus genes encompassed many well-known genes with the potential to dis-
tinguish subtypes. In addition to three Pam50 genes; ERBB2, ESR1 and FOXA1 [57], the con-
sensus set included; C1orf64 (ER-related factor, ERRF) which was down-regulated in TNBC,
in accordance with literature [58,59], CDK12, which was up-regulated in Her2 samples, sup-
ported by literature indicating that a total of 71% of Her2-enriched tumors overexpress this
gene [60]. Other genes of interest were CYP2B6 [61], MYLK3 [62], and SLURP1 [63].
We used CAMPP to perform WGCNA. In this example, WGCNA was generated only for
the DE genes. Fig 5 shows a subset of results from WGCNA with genes DE between breast can-
cer subtypes. Fig 5 sub-Figs; (I) 5A, a module dendrogram, (II) 5B, an example of a module
heatmap showing co-expression of genes in one of the small modules, module 2, and (III) 5C,
an example of a module interconnectivity plot, for the top 25% (default setting) most intercon-
nected genes in module 2. The six genes returned as the most interconnected in this module
were strongly associated with the Her2-enriched BC subtype. These genes included ERBB2
(HER2 itself), GRB7 (a Pam50 classifier gene) and MIEN1, CDK12, PGAP3, and TCAP, all of
which are ERBB2 amplicon passenger genes [64–66].
Lastly, to evaluate whether the variables found to partition BC subtypes were predicted to
interact, we used the pipeline to generate protein-protein interaction networks. Fig 6 shows
the top 100 strongest gene-gene interactions based on absolute logFC, and interaction score
for the comparison of Her2-enriched vs Luminal A, as an example. Results for comparison of
all subtypes pairwise may be found in the GitHub repository (CS1.zip). From the plot in Fig 6,
the two most interconnected genes in the contrast of Her2-enriched vs Luminal A samples,
were ERBB2 and ESR1 (Estrogen Receptor 1). As expected, ERBB2 was highly up-regulated,
PLOS COMPUTATIONAL BIOLOGY CAMPP - A standardized framework for the analysis of biological data
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while ESR1 was down-regulated in this comparison. Collectively, results highlight the utility of
the complementary R-frameworks implemented in the CAMPP wrapper.
Case Study 2
Analysis of N-glycans from LC Tandem Mass Spectrometry—Clustering, Tissue-Serum Corre-
lation and, Survival Analysis
For case study 2, we analyzed quantitative N-glycan data from liquid-chromatography tan-
dem mass spectrometry (LC-MS/MS). N-glycan abundances have been quantified from tumor
and normal interstitial fluids (TIFs and NIFs). In addition to interstitial fluids, we had paired
serum samples, enabling us to perform TIF-serum N-glycan abundance correlation analysis
with CAMPP. We have published the results of the in-depth analysis of these data here; [67].
Before differential abundance analysis, we used the pipeline to perform K-means clustering of
the samples. When running K-means with CAMPP, the user may specify labels to add to the
MDS plots generated, to see which clinical variables, if any, best explain the observed clusters.
From the evaluation of all k-means plot, the best number of clusters appeared to be two, one
corresponding to tumor samples and one to normal samples. S1 Fig shows the two clusters
with labels.
Fig 2. The output of a CAMPP data check. The gene used in this example is FAM27E2, randomly selected from the ten variable check plots. Top panel from the left;
Cullen and Frey graph showing skewness and kurtosis of normalized and transformed expression data and histogram with different distribution models overlayed.
Lower panel from left, quantile-quantile, and probability-probability plot.
https://doi.org/10.1371/journal.pcbi.1007665.g002
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After clustering analysis, we performed DAA and elastic-net regression, as described in the
section on variable selection and in Case Study 1. Cut-off for FDR < 0.05 and for elastic-net
regression alpha was set to = 0.5. DAA yielded a total of 20 N-glycan groups (12 up-regulated
in cancer vs normal and eight down-regulated in cancer vs. normal), while elastic-net returned
six N-glycan groups, all encompassed by the DA set—results may be found in the GitHub
repository (i.e., CS2.zip). Serum correlation analysis and survival analysis were performed on
the set of DE N-glycans. Fig 7 shows the results of the correlation analysis with paired N-glycan
Fig 3. Results of gene selection using DEA and elastic-net regression. The dataset contained ~ 15.000 genes and 80 samples, groups used for contrast were
estrogen positive (n = 61) vs estrogen negative samples (n = 19). Fig 3A is a multidimensional scaling plot showing the partitioning of samples (based on all
genes), colored by estrogen status. Fig 3B shows the overlap of results from elastic-net regression (alpha = 0.5) and differential expression analysis with
significance cutoffs logFC> 1 or< -1 and FDR< 0.05. Fig 3C depicts the performance statistics for elastic-net regression, e.g., 10-fold cross-validation errors
and area under the curve (AUC) scores for the test set. Elastic-net is run 10 times with different random seeds.
https://doi.org/10.1371/journal.pcbi.1007665.g003
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Fig 4. The heatmap in Fig 4 shows the partitioning breast cancer tissues into estrogen receptor-positive (ER+) samples and estrogen receptor-negative (ER-)
samples, based on the consensus set of variables from differential expression analysis and elastic-net regression. Green = ER+ samples and Purple = ER- samples.
Color scale of heatmap (blue to yellow) denotes log2 fold change.
https://doi.org/10.1371/journal.pcbi.1007665.g004
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abundances from TIFs and serum. Three N-glycan groups, GP1, GP37, and GP38 were found
to displayed significant correlation scores after correction for multiple testing. Fig 7A shows
correlation scores of all tested N-glycans, while 7B shows the individual scatter plots produced
for the three significant N-glycan groups. Lastly, Cox proportional hazard regression was per-
formed with correction for age at diagnosis as well as immune scores, as immune infiltration
has been shown to be associated with patient response to treatment and survival [68]. Fig 8
shows the hazard ratios for the DA N-glycan groups with confidence intervals. As seen from
Fig 5. Results of Weighted Gene Co-expression Network Analysis on dataset of ~ 15.000 genes and 80 samples. As the dataset contained
more than 5000 variables, WGCNA was performed in a block-wise manner to save computational time, in accordance with the WGCNA
reference manual [44]. Fig 5A shows the module clustering tree for the first block as an example. Fig 5B depicts the co-expression heatmap for
the small module 2, in which a set of six genes display highly correlated expression patterns. Fig 5C contains the top 25% (in this case five) most
interconnected genes from the small module 2, with module interconnectivity scores.
https://doi.org/10.1371/journal.pcbi.1007665.g005
Fig 6. Plot showing the top 100 best protein-protein (gene-gene) interaction pairs from the analysis of HER2-enriched vs Luminal A samples. Colors denote
the log fold change of a gene; yellow = up-regulated and blue = down-regulated. The size of the node shows the absolute log fold change, while the ordering from
left to right denotes the degree of node interconnectivity. The width of the arch represents the interaction score from the STRING database.
https://doi.org/10.1371/journal.pcbi.1007665.g006
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Fig 7. Results of correlation analysis with N-glycan abundances in interstitial fluids and paired serum samples. Dataset contained a total of 103
samples (51 normal interstitial fluids and 52 tumor interstitial fluids) with ~70 N-glycan groups (165 N-glycans). Fig 7A shows the correlation scores for
differentially abundant N-glycan groups, three of these, GP1, GP37, and GP38 met the requirement for significance (corr> 0.5 and fdr< 0.05), y-
PLOS COMPUTATIONAL BIOLOGY CAMPP - A standardized framework for the analysis of biological data
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the figure, one N-glycan group, GP38, was significantly associated with overall survival, e.g., a
high level of TIF GP38 was predictive of a poor patient outcome.
Discussion
The CAMPP pipeline supports different types of analysis and will provide the user with graph-
ics to support results—all plots displayed in this publication were generated with CAMPP with
no or very minimal editing. CAMPP is implemented in such a way that a user is able to run
the pipeline on their local computer on datasets with up to 300–500 samples and 40.000 vari-
ables. As an example of this, the user manual, (https://github.com/ELELAB/CAncer-
bioMarker-Prediction-Pipeline-CAMPP/blob/master/CAMPPManual.pdf) includes the anal-
ysis of breast cancer RNA-seq data from TCGA (416 samples and ~ 32.000 gene transcripts,
after filtering). For larger datasets, CAMPP may become slow and memory consuming if
WGCNA is performed. In this case, it is advisable to run the pipeline on a server, allocating
more cores—Table 2 shows run time, and memory use by CAMPP applied to datasets of dif-
ferent sizes.
We compared the pipeline to other open-source tools for throughput data analysis, found
to have similar functionalities and user demographics. S1 Table shows a summary of the CAn-
cer bioMarker Prediction Pipeline (CAMPP), alongside a selection of other software [69–79].
As seen from this comparison the strengths of CAMPP lie both in (I) the variety of analysis it
can perform, (II) that the pipeline is able to handle different types of quantitative biological
axis = Spearman correlation coefficient. Fig 7B shows the individual correlation plots for the three significant N-glycan groups, x-axis = tumor interstitial
fluid abundance and y-axis = serum abundance.
https://doi.org/10.1371/journal.pcbi.1007665.g007
Fig 8. Results of survival analysis (cox-proportional hazard regression) with correction for patient age at diagnosis and tumor infiltrating lymphocyte status
(TILs). Survival analysis was run on the set of differentially expressed N-glycan groups. Only one N-glycan, GP38, was significant after correction for multiple
testing. Hazard ratios are displayed on a log2 scale with confidence intervals, x-axis = N-glycan groups, and y-axis = log2 hazard ratio.
https://doi.org/10.1371/journal.pcbi.1007665.g008
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data, from different platforms and (III) that it is flexible in terms of modeling co-variates. Also,
unlike most of the other tools, CAMPP employs limma for DE analysis. One advantage of
limma is that this software has been shown to perform well even with very small sample sizes
[17,40,80], a low power scenario that is not unfamiliar in biomedical research. Lastly, the pipe-
line is relatively fast to run even with larger gene expression datasets and somewhat robust to
different operating systems as it relies on R/Rstudio, which are continuously maintained to fol-
low system updates.
We have tried to ensure that the software is user-friendly to those without much programming
experience. However, we aware that this tool requires the user to work in a terminal environment
and to have R and command-line tools installed on their computer. As such, this pipeline is tar-
geted towards bioinformatic software users and computational-inclined bio-researchers.
In summary, CAMPP is an R-based command-line tool for downstream analysis of high
throughput biological data. CAMPP was developed with the intent to provide the biomedical
community with an automated way of screening for biomolecules of interest while ensuring a
standardized framework for data normalization and statistical analysis.
Availability and future directions
The CAncer bioMarker Prediction Pipeline (CAMPP) is open source and may be downloaded
from the github repository: https://github.com/ELELAB/CAncer-bioMarker-Prediction-
Pipeline-CAMPP.
Table 2. Table showing run times and memory usage for CAMPP applied to datasets of different sizes. As the weighted gene co-expression network analysis
(WGCNA) and estimation of optimal number of clusters for k-means are by far the slowest and most memory consuming processes, we have provided estimates with and
without these two analyses. The [.] denotes that a given analysis was not performed on a dataset.
Type of Data Biological Type Number of
Samples
Number of
Variables
WGCNA
Variables
K-
means
Interaction
Networks
Run Time in
Minutes
Memory Usage
in GB
Dataset
1
Mass
Spectrometry
N-glycans 80 165 All Yes . 0,3 0,6
Dataset
2
Array mRNA 80 15000 . . . 0,8 0,8
Dataset
2
Array mRNA 80 15000 Differentially
Expressed
Yes . 3,3 1,4
Dataset
2
Array mRNA 80 15000 All . . 12 7,8
Dataset
2
Array mRNA 80 15000 All Yes . 15,5 7,8
Dataset
3
Array + Array microRNA
+ mRNA
80 15754 . . Yes 4 1,6
Dataset
3
Array + Array microRNA
+ mRNA
80 15754 Differentially
Expressed
Yes Yes 5,6 1,6
Dataset
3
Array + Array microRNA
+ mRNA
80 15754 All . Yes 16 7,8
Dataset
4
Array mRNA 80 29274 . . . 1,2 0,9
Dataset
4
Array mRNA 80 29274 Differentially
Expressed
Yes . 3,8 1,9
Dataset
5
Sequencing mRNA 416 55150 . . . 3 1,5
Dataset
5
Sequencing mRNA 416 55150 Differentially
Expressed
. . 3,5 1,4
Dataset
5
Sequencing mRNA 416 55150 Differentially
Expressed
Yes . 12,8 2,3
https://doi.org/10.1371/journal.pcbi.1007665.t002
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As it may be of interest for CAMPP users to understand in detail, how the underlying code
and functions work, our plan for the future is to include an R-markdown code run-though.
This way the code may more easily be copied and modified and improved, hopefully for the
benefit of the computational biology community and for the pipeline itself, as code suggestions
and revisions are welcome.
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